Fenwick Represents Diagonal Therapeutics in $125M Series B Financing

Fenwick represented Diagonal Therapeutics, a biotechnology company developing disease-modifying clustering antibodies that correct dysregulated signaling in severe genetic diseases, in its $125 million Series B financing. The round was co-led by Sanofi Ventures and Janus Henderson Investors with participation from Deep Track Capital, EcoR1 Capital, Logos Capital, Balyasny Asset Management L.P., Woodline Partners LP, Atlas Venture, BVF Partners, Lightspeed Venture Partners, RA Capital Management, Frazier Life Sciences, Viking Global Investors, RV Invest, Velosity Capital, Biovision Ventures, and Checkpoint Capital.

Diagonal Therapeutics will use the funds to support advancement of DIAG723, a disease-modifying clustering antibody designed to correct the underlying cause of hereditary hemorrhagic telangiectasia (HHT) and pulmonary arterial hypertension (PAH), conditions that collectively impact hundreds of thousands of people around the world. More information can be obtained here.

The Fenwick transaction team was led by corporate partners Effie Toshav and Matt Rossiter and included associates James Li, Morgan Clarke, and Joshua Lefkowitz.